Pfizer enters final stretch of late-stage COVID-19 vaccine trial

Phase III trial of 44,000 volunteers now needs fewer than 2000 people to be fully enrolled. The vaccine, which requires 2 doses 28 days apart, has been tested in 36,000 people. Potential for submission of Emergency Use Authorization with FDA in November is still a possibility.

Source:

Biospace Inc.